{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:53:17Z","timestamp":1791582797667,"version":"4.3.4"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.disamonth.2026.102231","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:10:08Z","timestamp":1791580208000},"page":"102231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Status Of GLP-1 drugs and their application in treating substance use disorders: A systematic review"],"prefix":"10.1016","author":[{"given":"Pugazhendi","family":"Inban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashita","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kakarala","family":"Rushika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halla","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dastan","family":"Kudaiarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadarshi","family":"Prajjwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jobby","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.disamonth.2026.102231_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1655575","article-title":"Global trends and inequalities in the burden of drug use disorders: a comprehensive analysis from 1990 to 2021 with future projections","volume":"13","author":"Zhou","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.disamonth.2026.102231_bib0002","article-title":"Global burden of disease due to opioid, amphetamine, cocaine, and cannabis use disorders, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"20","author":"Zhu","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.disamonth.2026.102231_bib0003","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1038\/s41380-026-03503-9","article-title":"The global burden of mental and substance use disorders among adolescents and young adults","volume":"31","author":"Zhao","year":"2026","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.disamonth.2026.102231_bib0004","unstructured":"Global status report on alcohol and health and treatment of substance use disorders n.d. https:\/\/www.who.int\/publications\/i\/item\/9789240096745 (accessed April 2, 2026)."},{"key":"10.1016\/j.disamonth.2026.102231_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.addbeh.2024.108242","article-title":"Pharmacological treatment for substance use disorder: a systematic review","volume":"163","author":"Mateu-Moll\u00e1","year":"2025","journal-title":"Addict Behav"},{"key":"10.1016\/j.disamonth.2026.102231_bib0006","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/07067437241312683","article-title":"Limitations and future directions in pharmacological treatment for amphetamine-type stimulant use disorder","volume":"70","author":"Bahji","year":"2025","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.disamonth.2026.102231_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.00569","article-title":"One is not enough: understanding and modeling polysubstance use","volume":"14","author":"Crummy","year":"2020","journal-title":"Front Neurosci"},{"issue":"15","key":"10.1016\/j.disamonth.2026.102231_bib0008","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s40265-020-01373-1","article-title":"Non-opioid treatments for opioid use disorder: rationales and data to date","volume":"80","author":"Chalhoub","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.disamonth.2026.102231_bib0009","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-019-00637-z","article-title":"Buprenorphine treatment for opioid use disorder: an overview","volume":"33","author":"Shulman","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.disamonth.2026.102231_bib0010","article-title":"Glucagon-like peptide 1 receptor agonists in substance use disorders: a systematic review of ClinicalTrials.Gov","volume":"23","author":"Patil","year":"2026","journal-title":"Addict Behav Rep"},{"key":"10.1016\/j.disamonth.2026.102231_bib0011","unstructured":"National statistics on relapse rates for various addictions - addiction group n.d. https:\/\/www.addictiongroup.org\/resources\/relapse-rates-statistics\/(accessed April 2, 2026)."},{"key":"10.1016\/j.disamonth.2026.102231_bib0012","first-page":"85","article-title":"Neurobiology of addiction","author":"Semaan","year":"2023","journal-title":"Pharmacol Treat Subst Abuse: Evid-Outcome-Based Perspect"},{"key":"10.1016\/j.disamonth.2026.102231_bib0013","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11883-025-01319-6","article-title":"The expanding scope of GLP-1 receptor agonists: six uses beyond diabetes","volume":"27","author":"Sheth","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.disamonth.2026.102231_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103363","article-title":"The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions","volume":"86","author":"Moiz","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.disamonth.2026.102231_bib0015","article-title":"A comprehensive review of the role of GLP-1 agonists in weight management and their effect on metabolic parameters such as blood glucose, cholesterol, and blood pressure","volume":"16","author":"Gul","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.disamonth.2026.102231_bib0016","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.disamonth.2026.102231_bib0017","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of Central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am J Med"},{"key":"10.1016\/j.disamonth.2026.102231_bib0018","article-title":"Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.disamonth.2026.102231_bib0019","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.2147\/DDDT.S559919","article-title":"The clinical application of GLP-1RAs and GLP-1\/GIP dual receptor agonists based on pharmacological mechanisms: a review","volume":"19","author":"Liu","year":"2025","journal-title":"Drug Devel Ther"},{"key":"10.1016\/j.disamonth.2026.102231_bib0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3390\/medsci13030136","article-title":"Mechanisms of GLP-1 in modulating craving and addiction: neurobiological and translational insights","volume":"13","author":"Amorim Moreira Alves","year":"2025","journal-title":"Med Sci"},{"key":"10.1016\/j.disamonth.2026.102231_bib0021","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/29767342251351111","article-title":"Assessment of the potential of GLP-1 analogs in the treatment of addictions: a literature review","volume":"47","author":"Torres I","year":"2026","journal-title":"Subst Use Addctn J"},{"key":"10.1016\/j.disamonth.2026.102231_bib0022","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.biopsych.2026.01.011","article-title":"GLP-1 receptor agonist medications: interactions with addiction neurocircuitry","volume":"100","author":"Volkow","year":"2026","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.disamonth.2026.102231_bib0023","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41380-025-03261-0","article-title":"Glucagon-like peptide-1 receptor agonists as emerging therapeutics in bipolar disorder: a narrative review of preclinical and clinical evidence","volume":"31","author":"Llach","year":"2026","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.disamonth.2026.102231_bib0024","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqaf028","article-title":"GLP-1 receptor agonists: promising therapeutic targets for alcohol use disorder","volume":"166","author":"Jerlhag","year":"2025","journal-title":"Endocrinology"},{"key":"10.1016\/j.disamonth.2026.102231_bib0025","doi-asserted-by":"crossref","first-page":"bvaf141","DOI":"10.1210\/jendso\/bvaf141","article-title":"GLP-1 therapeutics and their emerging role in Alcohol and substance use disorders: an endocrinology primer","volume":"9","author":"Srinivasan","year":"2025","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.disamonth.2026.102231_bib0026","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3390\/brainsci15070702","article-title":"Glucagon-like peptide-1 receptor agonists: a new frontier in treating alcohol use disorder","volume":"15","author":"Oesterle","year":"2025","journal-title":"Brain Sci"},{"key":"10.1016\/j.disamonth.2026.102231_bib0027","article-title":"Glucagon-like peptide-1 receptor agonists and alcohol use: a real-word observational study in a large, integrated health care system","volume":"6","author":"Palzes","year":"2026","journal-title":"Biol Psychiatry Glob Open Sci"},{"key":"10.1016\/j.disamonth.2026.102231_bib0028","doi-asserted-by":"crossref","DOI":"10.1017\/neu.2025.6","article-title":"A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder","volume":"37","author":"Zheng","year":"2025","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.disamonth.2026.102231_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1702448","article-title":"The potential role of GLP-1 receptor agonists in substance use disorders - a systematic review","volume":"16","author":"V\u00f6lker","year":"2026","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.disamonth.2026.102231_bib0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Kruse Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.disamonth.2026.102231_bib0031","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40429-025-00657-4","article-title":"The potential utility of GLP-1 receptor agonist medications for addiction treatment: a narrative review of clinical and epidemiological evidence","volume":"12","author":"Yammine","year":"2025","journal-title":"Curr Addctn Rep"},{"key":"10.1016\/j.disamonth.2026.102231_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114565","article-title":"Targeting GLP-1 receptors to reduce nicotine use disorder: preclinical and clinical evidence","volume":"281","author":"Herman","year":"2024","journal-title":"Physiol Behav"},{"key":"10.1016\/j.disamonth.2026.102231_bib0033","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/dom.70198","article-title":"Psychiatric effects of GLP-1 receptor agonists: a systematic review of emerging evidence","volume":"28","author":"Sa","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102231_bib0034","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.biopsych.2026.03.1002","article-title":"GLP-1 receptor agonists in psychiatry: a pharmacoepidemiological scoping review","volume":"100","author":"Volkow","year":"2026","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.disamonth.2026.102231_bib0035","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.disamonth.2026.102231_bib0036","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.1375-25.2025","article-title":"GLP-1 receptor agonists and research to treat overeating and substance use disorders","volume":"45","author":"Guo","year":"2025","journal-title":"J Neurosci"},{"key":"10.1016\/j.disamonth.2026.102231_bib0037","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.3390\/jcm15072786","article-title":"Beyond glycemic control: gLP-1RA-based therapies and emerging targets Beyond the metabolic axis","volume":"15","author":"Matuszewski","year":"2026","journal-title":"J Clin Med"},{"key":"10.1016\/j.disamonth.2026.102231_bib0038","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.chest.2020.03.013","article-title":"Randomized Controlled trials","volume":"158","author":"Zabor","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.disamonth.2026.102231_bib0039","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.physbeh.2019.03.029","article-title":"The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: a systematic review","volume":"206","author":"Brunchmann","year":"2019","journal-title":"Physiol Behav"},{"key":"10.1016\/j.disamonth.2026.102231_bib0040","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/ADM.0000000000001347","article-title":"The efficacy of GLP-1 agonists in treating substance use disorder in patients: a scoping review","volume":"18","author":"Shen","year":"2024","journal-title":"J Addict Med"},{"key":"10.1016\/j.disamonth.2026.102231_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1613610","article-title":"Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis","volume":"16","author":"Xie","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.disamonth.2026.102231_bib0042","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4093\/dmj.2025.0242","article-title":"Exploring the side effects of GLP-1 receptor agonist: to ensure its optimal positioning","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.disamonth.2026.102231_bib0043","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194740","article-title":"The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications","volume":"136","author":"Jalleh","year":"2026","journal-title":"J Clin Invest"},{"key":"10.1016\/j.disamonth.2026.102231_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.112424","article-title":"Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: a systematic review of randomized trials","volume":"264","author":"Martinelli","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.disamonth.2026.102231_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol Behav"},{"key":"10.1016\/j.disamonth.2026.102231_bib0046","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.2165","article-title":"The Cochrane risk of bias assessment tool 2 (RoB 2) versus the original RoB: a perspective on the pros and cons","volume":"7","author":"Nejadghaderi","year":"2024","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.disamonth.2026.102231_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-14-45","article-title":"Newcastle-Ottawa scale: comparing reviewers' to authors' assessments","volume":"14","author":"Lo","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.disamonth.2026.102231_bib0048","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for Alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.disamonth.2026.102231_bib0049","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.disamonth.2026.102231_bib0050","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.disamonth.2026.102231_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.disamonth.2026.102231_bib0052","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.7326\/M23-2718","article-title":"Association of semaglutide with Tobacco use disorder in patients with type 2 diabetes?: target trial emulation using real-world data","volume":"177","author":"Wang","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.disamonth.2026.102231_bib0053","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.disamonth.2026.102231_bib0054","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/dom.70169","article-title":"Relative efficacy of GLP-1 and GLP-1\/GIP receptor agonists in the prevention of alcohol-use disorders using a target trial emulation approach","volume":"28","author":"Henney","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102231_bib0055","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-086886","article-title":"Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study","volume":"392","author":"Cai","year":"2026","journal-title":"BMJ"},{"key":"10.1016\/j.disamonth.2026.102231_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2026.1766770","article-title":"Association between GLP-1 receptor agonist use and substance use disorders among individuals with type 2 diabetes or obesity: a nested case-control study in the All of Us research program","volume":"17","author":"Abegaz","year":"2026","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.disamonth.2026.102231_bib0057","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-026-26474-6","article-title":"The use of GLP-1 receptor agonists and subsequent risk of nicotine-related events: a cross- sectional study","volume":"26","author":"Alsaleh","year":"2026","journal-title":"BMC Public Health"},{"key":"10.1016\/j.disamonth.2026.102231_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2024.102427","article-title":"Neurocircuitry underlying the actions of glucagon-like peptide 1 and peptide YY3-36 in the suppression of food, drug-seeking, and anxiogenesis","volume":"105","author":"Dumiaty","year":"2024","journal-title":"Neuropeptides"},{"key":"10.1016\/j.disamonth.2026.102231_bib0059","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.disamonth.2026.102231_bib0060","doi-asserted-by":"crossref","DOI":"10.2174\/0113816128443199260115135518","article-title":"Semaglutide and alcohol use disorder: breaking free of addiction?","volume":"32","author":"Papaetis","year":"2026","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.disamonth.2026.102231_bib0061","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jamapsychiatry.2025.3639","article-title":"Semaglutide and early-stage metabolic abnormalities in individuals with Schizophrenia spectrum disorders: a randomized clinical trial","volume":"83","author":"Sass","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.disamonth.2026.102231_bib0062","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.3390\/ijms26115338","article-title":"GLP-1 analogues in the neurobiology of addiction: translational insights and therapeutic perspectives","volume":"26","author":"Marquez-Meneses","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.disamonth.2026.102231_bib0063","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jamapsychiatry.2025.4308","article-title":"Prospects of GLP-1 therapies for addiction and mental health comorbidities-Quo Vadis?: a review","volume":"83","author":"Farokhnia","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.disamonth.2026.102231_bib0064","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3390\/jcm15041613","article-title":"Incretin-based therapies: a novel pathway in addiction treatment","volume":"15","author":"Dawid","year":"2026","journal-title":"J Clin Med"},{"key":"10.1016\/j.disamonth.2026.102231_bib0065","doi-asserted-by":"crossref","unstructured":"Jesu\u00edno L, Andrade O, Matos De Oliveira L, Correia G, De Oliveira Unaerp -Electro M, Hospital B, et al. Modulation of the incretin axis (GLP-1\/GIP) in behavioral compulsions: a new neuropsychopharmacology frontier 2026. https:\/\/doi.org\/10.21203\/RS.3.RS-9238201\/V1.","DOI":"10.21203\/rs.3.rs-9238201\/v1"},{"key":"10.1016\/j.disamonth.2026.102231_bib0066","doi-asserted-by":"crossref","unstructured":"El Nekidy WS, Hasan H, Abidi E, Al Sayegh L, Dajani RZ, El-Kaissi S, et al. Comparing the efficacy of liraglutide and semaglutide on weight loss: experience from the Middle East gulf region and literature review. JournalsSagepubComWS El Nekidy, H Hasan, E Abidi, L Al Sayegh, RZ Dajani, S El-Kaissi, SB Hegazin, J MallatHospital Pharmacy, 2025ojournalsSagepubCom 2025;60:432\u2013440. https:\/\/doi.org\/10.1177\/00185787251340645.","DOI":"10.1177\/00185787251340645"},{"key":"10.1016\/j.disamonth.2026.102231_bib0067","article-title":"Comparative efficacy and tolerability of tirzepatide versus semaglutide at varying doses for weight loss in non-diabetic adults with obesity: a network meta-analysis of randomized controlled trials","volume":"17","author":"Kasagga","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.disamonth.2026.102231_bib0068","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2147\/CLEP.S391819","article-title":"Efficacy and safety of liraglutide and semaglutide on weight loss in people with obesity or overweight: a systematic review","volume":"Volume 14","author":"Xie","year":"2022","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.disamonth.2026.102231_bib0069","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70127","article-title":"Once-weekly semaglutide versus Once-daily liraglutide for weight loss in adults: a meta-analysis of randomized controlled trials","volume":"18","author":"Hashmi","year":"2025","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.disamonth.2026.102231_bib0070","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/oby.70024","article-title":"GLP-1 receptor agonists and substance use disorders in older adults with type 2 diabetes: a target trial emulation","volume":"34","author":"Dai","year":"2026","journal-title":"Obes. (Silver Spring)"},{"key":"10.1016\/j.disamonth.2026.102231_bib0071","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/dom.70384","article-title":"Association between glucagon-like peptide-1 receptor agonists and risk of dementia in older adults with type 2 diabetes: a target trial emulation","volume":"28","author":"Zhou","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102231_bib0072","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1161\/CIRCULATIONAHA.125.075157","article-title":"Risk of heart failure hospitalization for GLP-1 receptor agonists versus DPP-4 inhibitors or SGLT-2 inhibitors in patients with type 2 Diabetes: a target trial emulation","volume":"153","author":"Xu","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.disamonth.2026.102231_bib0073","doi-asserted-by":"crossref","unstructured":"Kristensen FPB, Christensen DH, Callaghan BC, Nielsen JS, Andersen H, S\u00f8rensen HT, et al. Effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists on diabetic foot disease. 2026. https:\/\/doi.org\/10.7326\/ANNALS-25-01262.","DOI":"10.7326\/ANNALS-25-01262"},{"key":"10.1016\/j.disamonth.2026.102231_bib0074","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13098-025-02006-x","article-title":"Repurposing GLP-1 receptor agonists for alcohol use disorder: a systematic review and meta-analysis","volume":"18","author":"Nasrollahizadeh","year":"2026","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.disamonth.2026.102231_bib0075","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2026.4722","article-title":"GLP-1 receptor agonists and noncardiometabolic outcomes: an Umbrella review of meta-analyses","volume":"9","author":"Yang","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.disamonth.2026.102231_bib0076","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102231_bib0077","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s12325-026-03495-6","article-title":"Flash glucose monitoring system enhances glycemic control and metabolic health in people with type 2 diabetes on GLP-1RA-based therapy: real-world evidence","volume":"43","author":"Al Hayek","year":"2026","journal-title":"Adv Ther"},{"key":"10.1016\/j.disamonth.2026.102231_bib0078","unstructured":"Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists 2024."},{"key":"10.1016\/j.disamonth.2026.102231_bib0079","article-title":"Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review","volume":"37","author":"Au","year":"2025","journal-title":"Acta Neuropsychiatr"},{"key":"10.1016\/j.disamonth.2026.102231_bib0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40265-025-02263-0","article-title":"Safety and tolerability of glucagon-like peptide-1 receptor agonists: a state-of-the-art narrative review","volume":"86","author":"Kunutsor","year":"2026","journal-title":"Drugs"},{"key":"10.1016\/j.disamonth.2026.102231_bib0081","first-page":"1","article-title":"A clinical comprehensive evaluation of long-acting GLP-1 receptor agonists in type 2 diabetes management","volume":"19","author":"Chen","year":"2026","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.disamonth.2026.102231_bib0082","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s44220-025-00390-x","article-title":"An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders","volume":"3","author":"De Giorgi","year":"2025","journal-title":"Nat Ment Health"},{"key":"10.1016\/j.disamonth.2026.102231_bib0083","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/gastroent15010014","article-title":"GLP-1RA essentials in gastroenterology: side effect management, precautions for endoscopy and applications for gastrointestinal disease treatment","volume":"15","author":"Wan","year":"2024","journal-title":"Gastroenterol Insights"},{"key":"10.1016\/j.disamonth.2026.102231_bib0084","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/dmrr.1202","article-title":"The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review","volume":"27","author":"Aroda","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.disamonth.2026.102231_bib0085","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf784.4322","article-title":"GLP-1 RAs reduce mortality and cardiovascular events across the spectrum of treated patients: a systematic review and meta-analysis","volume":"46","author":"Galli","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.disamonth.2026.102231_bib0086","article-title":"Gastrointestinal adverse events associated with GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis","volume":"12","author":"Huang","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.disamonth.2026.102231_bib0087","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1111\/dom.70002","article-title":"Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: a population-based cohort study","volume":"27","author":"Her","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102231_bib0088","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1111\/dom.15822","article-title":"Newer glucose-lowering drugs and risk of suicidal ideation and behaviors: a network meta-analysis of randomized outcome trials","volume":"26","author":"Lu","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.disamonth.2026.102231_bib0089","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1601118","article-title":"Association between SGLT-2 inhibitors and suicide risk in type 2 diabetes and bipolar: a real-world cohort study","volume":"16","author":"Chang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.disamonth.2026.102231_bib0090","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1038\/s41380-026-03619-y","article-title":"GLP-1 receptor agonists and risk of suicide or suicide attempts - a nationwide cohort and self-controlled case series study","volume":"31","author":"Stanislaus","year":"2026","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.disamonth.2026.102231_bib0091","doi-asserted-by":"crossref","DOI":"10.18103\/mra.v14i2.7249","article-title":"The potential of glucagon-like peptide-1 receptor agonists in addictive disorders","volume":"14","author":"Breit","year":"2025","journal-title":"Med Res Arch"},{"key":"10.1016\/j.disamonth.2026.102231_bib0092","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.neuroscience.2023.07.031","article-title":"Neuroimmune mechanisms of opioid use disorder and recovery: translatability to Human studies, and future research directions","volume":"528","author":"Butelman","year":"2023","journal-title":"Neuroscience"},{"key":"10.1016\/j.disamonth.2026.102231_bib0093","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/add.16626","article-title":"GLP-1R agonist medications for addiction treatment","volume":"120","author":"Volkow","year":"2025","journal-title":"Addctn (Abingdon Engl)"},{"key":"10.1016\/j.disamonth.2026.102231_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2026.121802","article-title":"Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: a WHO VigiBase study","volume":"407","author":"Aboukaoud","year":"2026","journal-title":"J Affect Disord"},{"key":"10.1016\/j.disamonth.2026.102231_bib0095","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.3390\/healthcare13222958","article-title":"Evaluating suicidal risk in GLP-1RA therapy: an umbrella review of meta-analytic evidence","volume":"13","author":"\u0218tef\u0103nescu","year":"2025","journal-title":"Healthcare"},{"key":"10.1016\/j.disamonth.2026.102231_bib0096","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2215-0366(26)00014-3","article-title":"Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study","volume":"13","author":"Taipale","year":"2026","journal-title":"Lancet Psychiatry"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502926001690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502926001690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:10:20Z","timestamp":1791580220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502926001690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":96,"alternative-id":["S0011502926001690"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2026.102231","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Status Of GLP-1 drugs and their application in treating substance use disorders: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2026.102231","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102231"}}